论文部分内容阅读
目的观察分析较低剂量氟哌噻吨美利曲辛治疗功能性消化不良的疗效。方法选取我院自2013年1月至2015年1月这段时期内收治的136例功能性消化不良患者作为临床研究对象,将其随机分成研究组68例和对照组68例,两组患者均给予常规处理及对症治疗,同时在此基础上对研究组的患者采用较低剂量氟哌噻吨美利曲辛治疗,观察比较两组患者的临床疗效、焦虑和抑郁评分及不良反应情况。结果研究组患者的总治疗有效率显著高于对照组患者,数据差异具有统计学意义(P<0.05);研究组患者的焦虑和抑郁评分显著低于对照组患者,数据差异具有统计学意义(P<0.05);两组患者的不良反应发生率比较差异不显著(P>0.05)。结论采用较低剂量氟哌噻吨美利曲辛治疗功能性消化不良疗效显著,且不良反应较少,是一种安全有效的治疗方法,值得于临床上推广。
Objective To observe the curative effect of lower doses of flupentixol and melitracin on functional dyspepsia. Methods 136 patients with functional dyspepsia treated in our hospital from January 2013 to January 2015 were randomly divided into study group 68 cases and control group 68 cases, both groups were Given conventional treatment and symptomatic treatment, at the same time on the basis of the study group of patients taking flupentixol at a lower dose of metyralnit treatment, observed and compared two groups of patients with clinical efficacy, anxiety and depression scores and adverse reactions. Results The total effective rate of treatment group was significantly higher than that of the control group (P <0.05). The anxiety and depression scores of the study group were significantly lower than those of the control group (P <0.05) P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusions The efficacy of flupentixol and melitracen in treating patients with functional dyspepsia is significant and the adverse reaction is less. It is a safe and effective treatment and worthy of clinical promotion.